BUSINESS MODEL

Cebert Pharmaceuticals, Inc. is a privately-held company that operates on sound business practices. Initially, Cebert partnered with institutional investors to fund operations as well as product acquisition and development opportunities. In May, 2000, Cebert Pharmaceuticals redeemed all preferred shares belonging to the institutional investors and downsized to become a lean, efficient, profitable organization. Since 2001, Cebert has acquired, licensed and developed products through strategic planning to maintain profitablility.

With the January, 2009 divestiture of the methadone product group to Roxane Labs/Boehringer Ingelheim, Cebert is investing in the development of additional products with anticipation of launching the next product in 2011.